Annual Review of Immunology | Development, Function, and Clinical Applications of CD8+ Regulatory T Cells

This study systematically reveals the mechanism by which CD8+ Tregs achieve specific immune regulation through recognition of self-peptides presented by Qa-1 and HLA-E, providing novel targeted strategies for autoimmune diseases and cancer immunotherapy.

 

Literature Overview

The article 'CD8+ Regulatory T Cells,' published in the Annual Review of Immunology, systematically explores the critical role of CD8+ regulatory T cells (Tregs) in immune tolerance. The review summarizes the developmental pathways, functional characteristics, and regulatory mechanisms of CD8+ Tregs in various disease models, with a particular focus on MHC-Ib molecule Qa-1 (mouse) and HLA-E (human) restricted T cell subsets. The study further reveals the restricted T cell receptor (TCR) repertoire, the central regulatory role of the transcription factor Helios, and the mechanism of eliminating activated CD4+ T cells in a perforin-dependent manner. These findings provide new insights into the maintenance of immune homeostasis.

Background Knowledge

Currently, the treatment of autoimmune diseases such as multiple sclerosis (MS) and systemic lupus erythematosus (SLE) still faces challenges including strong non-specific immune suppression and insufficient long-term efficacy. Although CD4+ FOXP3+ Tregs have been extensively studied, they tend to lose stability or convert into pro-inflammatory phenotypes during in vitro expansion, limiting their clinical application. In contrast, CD8+ Tregs have emerged as a research hotspot due to their antigen-specific cytotoxic capabilities. However, CD8+ Tregs lack stable surface markers, and their development depends on non-classical MHC-Ib molecules such as Qa-1/HLA-E, making identification and expansion difficult. This study focuses on deciphering the TCR specificity and signaling pathways of CD8+ Tregs, particularly the roles of Ly49/KIR receptors and the Helios transcription factor, thereby providing a theoretical foundation for developing antigen-specific immunotherapies.

 

 

Research Methods and Experiments

The authors utilized various genetically engineered mouse models, including Qa-1^−/−, Qa-1-D227K mutant mice, and TCR transgenic mice, combined with bone marrow chimera systems, to verify that the thymic development of CD8+ Tregs depends on the interaction between Qa-1–self-peptide complexes and the TCR. Through tetramer sorting and single-cell TCR sequencing, TRAV9N3 and TRBV12–1/2 were identified as key TCR gene segments. Additionally, the EAE model was used to evaluate the function of CD8+ Tregs in neuroinflammation, and the regulatory activity of KIR+ CD8+ T cells was validated in human samples. Key evidence includes: in Qa-1-D227K mice, the frequency of CD8+ Tregs significantly decreased and failed to control Tfh cell expansion, leading to autoimmune phenotypes; in contrast, overexpression of the FL9–68 superagonist peptide specifically expanded CD8+ Tregs and suppressed disease progression.

Key Conclusions and Perspectives

• CD8+ Tregs develop in the thymus by recognizing Qa-1–self-peptide complexes, a process dependent on TCR signaling and Helios transcription factor expression, suggesting that Helios is a key regulatory node for stable phenotypes and provides guidance for future Treg stability studies
• CD8+ Tregs specifically eliminate activated CD4+ T cells (e.g., Tfh) expressing Qa-1 through a perforin-dependent mechanism to maintain tolerance, indicating that targeting Qa-1+ T cells could enable precise immune regulation and offer a new direction for treating autoimmune diseases
• Human KIR+ CD8+ T cells are the homologous population of mouse Ly49+ Tregs, and their impaired function is associated with active phases of multiple sclerosis, suggesting KIR could serve as a potential biomarker to guide clinical monitoring strategies
• The FL9–68 superagonist peptide can efficiently activate CD8+ Tregs and suppress EAE and transplant rejection, indicating that synthetic peptide vaccines could be used to expand antigen-specific Tregs, advancing drug development toward antigen-specific immune tolerance induction

Research Significance and Prospects

This study provides a systematic framework for understanding the immune tolerance mechanisms mediated by CD8+ Tregs, emphasizing their non-redundant role in maintaining immune homeostasis. Compared to traditional broad-spectrum immunosuppression, therapies targeting HLA-E–peptide complexes offer the potential for more precise immune regulation, reducing risks of infection and tumorigenesis. Moreover, the age-related functional decline of CD8+ Tregs suggests they may be impaired in elderly patients with autoimmune diseases, necessitating strategies to enhance their survival or function.

In terms of disease modeling, humanized HLA-E mice combined with KIR+ TCR transgenic models will help evaluate human-specific immune regulatory pathways. Meanwhile, nanoparticle delivery of HLA-E–peptide complexes could bypass the blood-brain barrier, offering novel therapeutic approaches for central nervous system diseases such as multiple sclerosis.

 

 

Conclusion

From bench to bedside, research on CD8+ regulatory T cells is progressively transitioning from mechanistic exploration to translational applications. By specifically eliminating pathogenic T cells in a Qa-1/HLA-E-dependent manner, they avoid the side effects of non-specific immunosuppression, making them ideal candidates for treating autoimmune diseases and preventing transplant rejection. In the future, immunotherapies based on superagonist peptides or nanocarriers may enable in vivo expansion of CD8+ Tregs and restoration of immune tolerance. Furthermore, the frequency and function of KIR+ CD8+ T cells could serve as biomarkers for disease activity in multiple sclerosis or SLE, facilitating precision diagnosis and treatment. Combined with gene-editing animal models and pharmacological evaluation platforms, this research lays a solid foundation for developing next-generation antigen-specific immunotherapies, potentially reshaping the care paradigm for autoimmune diseases.

 

Veena K Vuttaradhi, Clotilde M Vermelle, John Y Choi, Jamil R Azzi, and Harvey Cantor. CD8+ Regulatory T Cells. Annual review of immunology.